FSI Stanford Publications

Alglucerase for Gaucher's Disease: Dose, Costs, and Benefits

Journal Article

Authors
E Beutler
Alan M. Garber - Stanford University

Published by
PharmacoEconomics, Vol. 5, page(s) 453-459
1994

Publications of interest

Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease
Alan M. Garber, A.E. Clark, D.P. Goldman, M.E. Gluck
Washington, D.C.: U.S. Government Printing Office (1992)
Effect of Assessment Method and Respondent Population on Utilities Elicited for Gaucher Disease, The
AE Clarke, Mary K. Goldstein, D Michelson, Alan M. Garber, LA Lenert
Quality of Life Research vol. 6 (1997)
Costs and Benefits of Prenatal Screening for Cystic Fibrosis
Alan M. Garber, J.P Fenerty
Medical Care vol. 29 (1991)
Assessing the benefits and costs of new therapies for hepatitis B virus infection
Douglas K. Owens, Martin Black
Annals of Internal Medicine vol. 142, 10 (2005)

Assessing the Costs and Benefits of Screening for HIV
Swati Tole, DK Owens
Vaccinate Early and Often: Health Benefits and Costs of Pandemic Response Strategies for Pandemic (H1N1) 2009 and Influenza A (H5N1, or "Avian Flu")
Douglas K. Owens, Alan M. Garber, David Hutton, Nayer Khazeni
The Benefits and Costs of Health Plan Choice: The Case of Medicare Part D Prescription Drug Plans
M. Kate Bundorf
Sverdlovsk Revisited: Low-Dose Human Response to Inhalation Anthrax
Dean Wilkening